Pernix Therapeutics Holdings Sets New 12-Month High at $9.23 (PTX)
Shares of Pernix Therapeutics Holdings (NYSE:PTX) hit a new 52-week high on Thursday , ARN reports. The stock traded as high as $9.23 and last traded at $9.10, with a volume of 574,340 shares traded. The stock had previously closed at $8.99.
A number of research firms have recently commented on PTX. Analysts at Citigroup Inc. upgraded shares of Pernix Therapeutics Holdings from a “hold” rating to a “buy” rating in a research note on Tuesday, May 27th. Separately, analysts at Aegis upgraded shares of Pernix Therapeutics Holdings from a “hold” rating to a “buy” rating in a research note on Tuesday, May 27th. Finally, analysts at Needham & Company LLC upgraded shares of Pernix Therapeutics Holdings from a “buy” rating to a “strong-buy” rating in a research note on Thursday, May 15th. They now have a $10.00 price target on the stock, up previously from $6.30. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the company. Pernix Therapeutics Holdings currently has an average rating of “Hold” and an average target price of $4.67.
The stock’s 50-day moving average is $6.81 and its 200-day moving average is $4.3. The company’s market cap is $343.7 million.
Pernix Therapeutics Holdings (NYSE:PTX) last announced its earnings results on Monday, May 12th. The company reported ($0.26) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.05) by $0.21. The company had revenue of $19.10 million for the quarter, compared to the consensus estimate of $23.65 million. Analysts expect that Pernix Therapeutics Holdings will post $-0.18 EPS for the current fiscal year.
Pernix Therapeutics Holdings, Inc (NYSE:PTX) is a specialty pharmaceutical company focused on the sales, marketing and development of branded and generic pharmaceutical products for pediatric and adult indications in a range of therapeutic areas.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.